KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Accumulated Expenses (2018 - 2025)

Historic Accumulated Expenses for Esperion Therapeutics (ESPR) over the last 8 years, with Q3 2025 value amounting to $18.6 million.

  • Esperion Therapeutics' Accumulated Expenses fell 314.85% to $18.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $18.6 million, marking a year-over-year decrease of 314.85%. This contributed to the annual value of $19.6 million for FY2024, which is 2162.17% down from last year.
  • Per Esperion Therapeutics' latest filing, its Accumulated Expenses stood at $18.6 million for Q3 2025, which was down 314.85% from $15.5 million recorded in Q2 2025.
  • Esperion Therapeutics' Accumulated Expenses' 5-year high stood at $48.8 million during Q1 2021, with a 5-year trough of $5.4 million in Q4 2022.
  • Over the past 5 years, Esperion Therapeutics' median Accumulated Expenses value was $23.1 million (recorded in 2024), while the average stood at $23.7 million.
  • Over the last 5 years, Esperion Therapeutics' Accumulated Expenses had its largest YoY gain of 36070.77% in 2023, and its largest YoY loss of 5725.74% in 2023.
  • Over the past 5 years, Esperion Therapeutics' Accumulated Expenses (Quarter) stood at $7.0 million in 2021, then dropped by 22.63% to $5.4 million in 2022, then skyrocketed by 360.71% to $25.0 million in 2023, then fell by 21.62% to $19.6 million in 2024, then fell by 4.86% to $18.6 million in 2025.
  • Its Accumulated Expenses stands at $18.6 million for Q3 2025, versus $15.5 million for Q2 2025 and $16.6 million for Q1 2025.